Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds

BACKGROUND: Molecular targeted therapy for non-small cell lung carcinoma (NSCLC) is restricted due to resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). This study evaluated the effects of dual targeting of MEK and PI3K in human EGFR-TKI resistant NSCLC cell lin...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Ge-Ping, Shi, Min, Wang, Dan, Wu, Jiong-He, Wang, Peng, Gong, Mei-Liang, Zhang, Zhi-Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252311/
https://www.ncbi.nlm.nih.gov/pubmed/34210314
http://dx.doi.org/10.1186/s12890-021-01571-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252311/
https://www.ncbi.nlm.nih.gov/pubmed/34210314
http://dx.doi.org/10.1186/s12890-021-01571-x

Ejemplares similares